Assertio Holdings, Inc. (NASDAQ:ASRT) Director James L. Tyree Sells 44,643 Shares of Stock

Assertio Holdings, Inc. (NASDAQ:ASRTGet Rating) Director James L. Tyree sold 44,643 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $2.36, for a total transaction of $105,357.48. Following the transaction, the director now owns 210,451 shares of the company’s stock, valued at $496,664.36. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of NASDAQ ASRT opened at $2.69 on Tuesday. The company has a market cap of $122.21 million, a PE ratio of 44.83 and a beta of 1.61. Assertio Holdings, Inc. has a 12 month low of $0.85 and a 12 month high of $3.52. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.90 and a quick ratio of 0.71. The company has a 50-day simple moving average of $2.61 and a 200-day simple moving average of $2.22.

Assertio (NASDAQ:ASRTGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.11. Assertio had a net margin of 2.68% and a return on equity of 3.21%. During the same quarter in the prior year, the firm earned $0.12 earnings per share. On average, analysts anticipate that Assertio Holdings, Inc. will post 0.37 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its position in shares of Assertio by 10.2% in the third quarter. Morgan Stanley now owns 72,444 shares of the company’s stock worth $66,000 after acquiring an additional 6,731 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Assertio by 2.2% in the third quarter. Geode Capital Management LLC now owns 344,331 shares of the company’s stock worth $311,000 after acquiring an additional 7,525 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Assertio in the fourth quarter worth approximately $28,000. Advisor Group Holdings Inc. boosted its position in shares of Assertio by 2,983.7% in the first quarter. Advisor Group Holdings Inc. now owns 13,229 shares of the company’s stock worth $38,000 after acquiring an additional 12,800 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Assertio in the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 15.64% of the company’s stock.

Several research firms have weighed in on ASRT. StockNews.com upgraded shares of Assertio from a “buy” rating to a “strong-buy” rating in a report on Friday. Zacks Investment Research upgraded shares of Assertio from a “hold” rating to a “strong-buy” rating and set a $2.50 target price for the company in a report on Thursday, May 12th.

About Assertio (Get Rating)

Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.

See Also

Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.